LASEK better than Epi-LASIK

Article

LASEK produces better safety and efficacy outcomes than Epi-LASIK, according to a study published in the September edition of the American Journal of Ophthalmology.

Recent Videos
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
On the 75th anniversary of the IOL, modern surgeons pay tribute

On the 75th anniversary of the IOL, modern surgeons pay tribute

By Artemis Matsou, MD, MRCP(UK), FEBOS-CR, FEBO, PgDip CRS; and Richard Packard, MD, FRCS, FRCOphth
November 25th 2024
Article

At the ESCRS meeting, Sir Harold Ridley’s legacy was put on display in a pop-up museum installation

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A young boy inserts a contact lens while an adult supervises. ©andrey – stock.adobe.com

Incidence of microbial keratitis associated with overnight orthokeratology

Lynda Charters
November 21st 2024
Article

The incidence was comparable to that of daily wear soft contact lenses

A syringe against a multicolor background, with a drip of liquid at the end of the needle. Image credit: ©iloli – stock.adobe.com

European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis

Sydney M Crago
November 20th 2024
Article

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

A European Union delegate signs a document while an EU flag is visible on the desk. Image credit: ©pressmaster – stock.adobe.com

CHMP issues positive opinion for marketing authorisation of aflibercept biosimilar FYB203 (Formycon)

Sydney M Crago
November 19th 2024
Article

The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union

The FDA logo on a laptop computer. Image credit: ©monticellllo – stock.adobe.com

US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)

Hattie Hayes;Jordana Joy
November 19th 2024
Article

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

© 2024 MJH Life Sciences

All rights reserved.